Items Tagged ‘dlbcl’

September 3rd, 2014

Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Reported to be Effective in Aggressive Non-Hodgkin’s Lymphoma at the National Cancer Institute (NCI)

By

SANTA MONICA, Calif., Aug. 25, 2014 (GLOBE NEWSWIRE) — Kite Pharma, Inc., (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, announced the publication of clinical results in a cohort of patients demonstrating the potential to treat aggressive non-Hodgkin’s lymphoma with an anti-CD19 chimeric […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, anti-CD19, dlbcl, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, News, nhl, Non-Hodgkin's Lymphoma, Recurrent Non-Hodgkin's Lymphoma, T cell therapy


May 28th, 2014

Lenalidomide Added to R-CHOP21 Therapy Shows High Response in Elderly, Untreated Large B-Cell Lymphoma Patients

By

Researchers reported in the journal The Lancet Oncology that the addition of lenalidomide to the standard R-CHOP21 regimen elicited a high response rate in elderly patients with untreated diffuse large B-cell lymphoma. In addition, the combination therapy was deemed to be safe in this population. Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin […]

View full entry

Tags: Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, b-cell lymphoma, dlbcl, Follicular Lymphoma, Lymphoma, News, nhl, Non-Hodgkin's Lymphoma